此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

2014年5月23日 更新者:Joo-Youn Cho、Seoul National University Hospital

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity in Female Subjects Using Metabolomics

Identification and evaluation of endogenous markers for the assessment of CYP3A activity in female subjects using metabolomics

研究概览

详细说明

Eligibility for participation of this study will be determined from demographic information, medical history, physical examination, electrocardiogram(ECG) and clinical laboratory tests within 3 weeks before study drug administration. Subjects suitable for this study will be admitted to the Clinical Trials Center, Seoul National University Hospital on the day before dosing, and they will be overnight-fasted from 9 p.m. of Day -1. Urine collection is scheduled from 24 hours before midazolam administration to 24 hours after administration. Subjects will be dosed midazolam by intravenous around at 9 a.m. of Day 1. Subjects will perform scheduled procedures including clinical laboratory tests, electrocardiograms and pharmacokinetic samplings. Subjects will be discharged on Day 2 and visit the Clinical Trials Center for period 2, ketoconazole administration. After 3 days of ketoconazole administration, midazolam will be dosed with ketoconazole on Day 4 of period 2. Subjects will perform scheduled procedure and on period 3 rifampicin will be dosed for 9 days and on Day 10 of period 3 midazolam will be dosed with rifampicin. After subjects perform scheduled procedure, the study will be terminated 6-8 days after the end of period 3.

研究类型

介入性

注册 (实际的)

16

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Seoul、大韩民国、110-744
        • Seoul National Universtiy Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 50年 (成人)

接受健康志愿者

是的

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Age: Between 20 to 50 years of age, inclusive
  • Weight: Between 45 to 95 kg, within 17 - 28 of Body Mass Index
  • Menstruation cycle between 21 to 35 without contraceptive
  • Subject who agree contraception during the study
  • Subject who are reliable and willing to make themselves available during the study period, are willing to follow the study protocol, and give their written informed consent voluntarily

Exclusion Criteria:

  • History of hypersensitive reaction to medication (midazolam, ketoconazole, rifampicin)
  • History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease history or evidence of drug abuse
  • A subject whose lab test results are as follows; Liver function test (AST, ALT, GGT, ALP, LDH, Total bilirubin) > 1.25 X upper limit of reference range
  • A subject whose SBP is over 140 mmHg or below 90 mmHg and DBP is over 100 mmHg or below 50 mmHg
  • Presence or history of drug abuse or positive result in urine drug screening test
  • Blood donation during 2 months or apheresis during 1 month before the study
  • Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 14 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (if used medication is considered acceptable by investigator, patients can be included)
  • Use of alcohol over 21 units/weeks
  • Smoker who smoke more than 10 cigarettes per day
  • Participation in clinical trials of any drug within 60 days prior to the participation of the study
  • Use of grapefruit juice within 1 week before first dose
  • Use of caffeine drink within 3 days before first dose
  • Subject pregnant or breast-feeding
  • Judged to be inappropriate for the study by the investigator

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Midazolam

period 1: midazolam 1 mg IV single dose administration. period 2: midazolam 1 mg IV single dose after ketoconazole 400 mg oral dosing for 3 days.

period 3: midazolam 2.5 mg IV single dose after rifampicin 600 mg oral dosing for 10 days.

Midazolam 3 mg IV
其他名称:
  • Midazolam (Bukwang Pharm.Co., Ltd.)
ketoconazole 400 mg PO
其他名称:
  • Kaszole (Skynewpharm Inc.)
Rifampicin 600 mg PO
其他名称:
  • Rifampin (Yuhan Corp.)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Metabolomic profile
大体时间:-24--12h, -12-0h of every midazolam dosing
endogenous metabolite profiles such as steroid
-24--12h, -12-0h of every midazolam dosing

次要结果测量

结果测量
措施说明
大体时间
Pharmacokinetics
大体时间:0h, 10m, 20m, 30m, 45m, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h of every midazolam dosing
Cmax, AUClast of midazolam
0h, 10m, 20m, 30m, 45m, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h of every midazolam dosing

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Joo-Youn Cho, PhD、Seoul National University Hospital

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年12月1日

初级完成 (实际的)

2013年9月1日

研究完成 (实际的)

2013年9月1日

研究注册日期

首次提交

2012年12月26日

首先提交符合 QC 标准的

2013年1月1日

首次发布 (估计)

2013年1月4日

研究记录更新

最后更新发布 (估计)

2014年5月26日

上次提交的符合 QC 标准的更新

2014年5月23日

最后验证

2014年5月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅